HR+/HER2-locally advanced or metastatic Breast Cancer Ibrance® MyTherapy App: Digital Therapy Support with comprehensive Functions for Breast Cancer Patients

被引：0
|
作者：
不详
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：344 / 344
页数：1
相关论文
共 50 条
  • [31] Ribociclib for post-menopausal women with HR+/HER2-advanced or metastatic breast cancer
    Zangardi, Mark L.
    Spring, Laura M.
    Blouin, Gayle C.
    Bardia, Aditya
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (11) : 1169 - 1176
  • [32] Validation of Claims Algorithm to Identify HR+/HER2-Metastatic Breast Cancer Patients
    Chin, Andi
    Wu, Xiyuan
    Ip, Queeny
    Lyle, Derek
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 : 620 - 620
  • [33] EU-Approval is obtained for Kisqali® (Ribociclib) as a First-Line Therapy of HR+/HER2-, locally advanced or metastatic Breast Cancer
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 (10) : 640 - 640
  • [34] WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT IN WOMEN WITH HR+/HER2-ADVANCED/ METASTATIC BREAST CANCER
    Wood, R.
    Mitra, D.
    DeCourcy, J.
    Iyer, S.
    VALUE IN HEALTH, 2017, 20 (05) : A123 - A123
  • [35] BUDGET IMPACT ANALYSIS OF PALBOCICLIB FOR THE TREATMENT OF PATIENTS WITH HR+/HER2-ADVANCED/METASTATIC BREAST CANCER IN BULGARIA
    Djambazov, S.
    Slavchev, G.
    Velchev, M.
    Vekov, T.
    VALUE IN HEALTH, 2018, 21 : S22 - S22
  • [36] Comparison of ctDNA profiles from HR+/HER2-low and HR+/HER2-0 advanced breast cancer patients
    Dobric, N.
    Dandachi, N.
    Klocker, E. V.
    Suppan, C.
    Graf, R.
    Hasenleithner, S.
    Jost, P. J.
    Heitzer, E.
    Balic, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S387 - S387
  • [37] Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
    Guarneri, Valentina
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (11) : 1549 - 1557
  • [38] Preferences of Canadian Patients and Physicians for Treatment of HR+/HER2-Advanced Breast Cancer
    Stellato, Daniel
    Thabane, Marroon
    Eichten, Caitlin
    Delea, Thomas E.
    CURRENT ONCOLOGY, 2021, 28 (01) : 491 - 508
  • [39] Biomarker analysis in HR+, HER2-, locally advanced, or metastatic breast cancer patients treated with buparlisib: results from BELLE-3
    Solovieff, Nadia
    Wang, Ying A.
    Sankaran, Banu
    Scheuer, Nicolas
    El-Hashimy, Mona
    Weber, Denis
    Sellami, Dalila
    Di Leo, Angelo
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [40] Mammographic density and disease-free survival in [HR+,HER2-] locally advanced breast cancer
    Rojas, K.
    Flores, R.
    Flores, C.
    Pinto, J.
    Gomez, H. L.
    Castaneda, C.
    BREAST, 2015, 24 : S103 - S103
12345